Why egg-based flu vaccines sometimes miss the mark
Most flu vaccines are made by growing the virus in chicken eggs, and that process can introduce small changes—called egg-adaptive mutations—that help the virus grow in eggs but also alter its surface proteins. Those changes can make the vaccine a slightly worse match for the flu strains actually circulating in people, which lowers its effectiveness. A 2025 review highlights that this is a well-established problem, and that it can even affect how your immune system 'imprints' on flu if you're vaccinated as a child, potentially reducing the benefit of flu shots for years [3].
The problem is especially noticeable with H3N2, a common and severe flu subtype. A 2022 lab study found that egg-based H3N2 vaccines (like Fluzone) failed to protect mice against infection with a wild-type H3N2 virus, while mRNA vaccines encoding the wild-type (non-egg-adapted) version of the virus did protect them [2]. That's a direct demonstration that the egg-adaptation problem isn't just theoretical—it can make a vaccine ineffective against the real virus.
What mRNA flu vaccines do differently
mRNA vaccines don't use eggs at all. Instead, they give your cells the genetic instructions to make a piece of the flu virus (the hemagglutinin protein) that your immune system then learns to attack. Because there's no egg-based growth step, there's no opportunity for egg-adaptive mutations to creep in. The 2022 study confirmed this: mRNA vaccines encoding the wild-type H3 protein produced antibodies that neutralized the wild-type virus much more effectively than antibodies from an egg-based vaccine, and they also triggered high levels of broadly reactive antibodies that target the stalk of the hemagglutinin protein—a bonus that may offer broader protection [2].
This isn't just a lab curiosity. A 2024 modeling study, based on real US flu seasons from 2017–2020, estimated that switching from egg-based to cell-based vaccines (which also avoid egg adaptation) would prevent 31–39% more symptomatic flu cases, 29–40% more outpatient visits, and 34–49% more deaths in people aged 0–64 [1]. While that study looked at cell-based vaccines, not mRNA specifically, it shows the potential magnitude of benefit from avoiding egg adaptation—and mRNA vaccines are another way to achieve that.
How much real-world protection can you expect?
The honest answer is: we don't yet have large-scale human effectiveness data for mRNA flu vaccines. The 2022 study was in mice, and the 2024 modeling study was based on cell-based vaccines, not mRNA. So while the evidence strongly suggests mRNA vaccines will be at least as good as egg-based ones—and likely better, especially in seasons where egg adaptation is a problem—the exact real-world advantage is still being tested in clinical trials.
One important caveat: the modeling study's estimates are based on assumptions about relative effectiveness, and the authors note that the main drivers of the benefit were the relative effectiveness in the 2017–2018 season and the burden estimates for later seasons [1]. That means the 31–39% figure is a projection, not a measured outcome. Still, the direction is consistent across the studies: avoiding egg adaptation is a clear win, and mRNA vaccines are a promising way to do that.
About These Sources
This answer is built on 3 peer-reviewed studies — published from 2022 to 2025, 2 from 2024 or later, 2 in Q1 journals — selected as the most relevant from 3 studies that passed quality screening, drawn from 47 papers retrieved from a database of over 500 million.
Sources used in this answer
Influenza burden averted with a cell-based quadrivalent seasonal influenza vaccine compared with egg-based quadrivalent seasonal influenza vaccine
A 2024 modeling study using US data from 2017–2020 estimated that cell-based vaccines (which avoid egg adaptation) would avert 31–39% more symptomatic flu cases, 29–40% more outpatient visits, and 34–49% more deaths compared to egg-based vaccines in people aged 0–64.
Nucleoside-Modified mRNA-Based Influenza Vaccines Circumvent Problems Associated with H3N2 Vaccine Strain Egg Adaptation
A 2022 mouse study showed that mRNA-LNP vaccines encoding wild-type H3N2 hemagglutinin elicited antibodies that neutralized the wild-type virus more effectively than an egg-based Fluzone vaccine, and protected mice against infection, whereas the egg-based vaccine did not.
The impact of egg adaptation and immune imprinting on influenza vaccine effectiveness
A 2025 review summarizes that egg adaptation can reduce vaccine effectiveness and may also cause suboptimal immune imprinting if first exposure is via an egg-adapted vaccine, potentially lowering the benefit of flu vaccination over a lifetime.